Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease
Daniel D TruongThe Parkinson’s and Movement Disorder Institute, Fountain Valley, CA, USAAbstract: Levodopa has been the gold standard therapy for the motor symptoms of Parkinson’s disease for more than three decades. Although it remains the most effective treatment, its long-term...
Main Author: | Daniel D Truong |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-03-01
|
Series: | Clinical Interventions in Aging |
Subjects: | |
Online Access: | https://www.dovepress.com/tolcapone-review-of-its-pharmacology-and-use-as-adjunctive-therapy-in--peer-reviewed-article-CIA |
Similar Items
-
The catechol-O-methyltransferase inhibitor, tolcapone, increases the bioavailability of unmethylated (-)-epigallocatechin-3-gallate in mice
by: Sarah C. Forester, et al.
Published: (2015-08-01) -
Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “off” Episodes: A Comprehensive Review
by: Amnon A. Berger, et al.
Published: (2020-12-01) -
Mucuna pruriens as adjunct therapy to levodopa in advanced Parkinson’s disease
by: Fernando Botello-Villagrana, et al.
Published: (2021-01-01) -
Inhibition of Catechol-O-methyltransferase Does Not Alter Effort-Related Choice Behavior in a Fixed Ratio/Concurrent Chow Task in Male Mice
by: Adrienne C. DeBrosse, et al.
Published: (2020-05-01) -
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
by: Werner Poewe, et al.
Published: (2010-08-01)